ChREBP promotes the differentiation of leukemia-initiating cells to inhibit leukemogenesis through the TXNIP/RUNX1 pathways

Targeting leukemia-initiating cells (LICs) is the key to eradicating leukemia and preventing its relapse. Recent studies have indicated that metabolic regulation may play a critical role in the maintenance of stemness in LICs, although the detailed mechanisms are poorly understood. Herein, we provide intriguing evidence showing that a glucose-responsive transcription factor, carbohydrate responsive element binding protein (ChREBP), served as a tumor suppressor rather than an oncogene, as previously described, to inhibit the development of acute myeloid leukemia by promoting the differentiation of LICs. Using an MLL-AF9-induced murine leukemia model, we demonstrated that the deletion of ChREBP resulted in the blockage of the differentiation of LICs and significantly reduced survival in ChREBP-null leukemic mice. However, ChREBP was not required for the normal repopulation abilities of hematopoietic stem cells. ChREBP promoted leukemia cell differentiation through the direct inhibition of RUNX1 or the transactivation of TXNIP to downregulate the RUNX1 level and ROS generation. Moreover, knockdown of ChREBP in human leukemia THP1 cells led to markedly enhanced proliferation and decreased differentiation upon PMA treatment. Collectively, we unraveled an unexpected role of ChREBP in leukemogenesis, which may provide valuable clues for developing novel metabolic strategies for leukemia treatment.

[1]  Howard Y. Chang,et al.  Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. , 2015, Cell stem cell.

[2]  R. Chapple,et al.  AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. , 2015, Cell stem cell.

[3]  R. Deberardinis,et al.  Hypoxic metabolism in human hematopoietic stem cells , 2015, Cell & Bioscience.

[4]  William J. Israelsen,et al.  Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis , 2014, Cell.

[5]  A. Harris,et al.  Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression , 2013, British Journal of Cancer.

[6]  N. Speck,et al.  Distinct temporal requirements for Runx1 in hematopoietic progenitors and stem cells , 2013, Development.

[7]  Masahiro Nakagawa,et al.  Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. , 2013, The Journal of clinical investigation.

[8]  N. Speck,et al.  Gata2 is required for HSC generation and survival , 2013, The Journal of experimental medicine.

[9]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[10]  J. D. Engel,et al.  Conditional Gata2 inactivation results in HSC loss and lymphatic mispatterning. , 2012, The Journal of clinical investigation.

[11]  S. Sugano,et al.  Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. , 2012, Blood.

[12]  A. F. Stewart,et al.  ChREBP Mediates Glucose-Stimulated Pancreatic β-Cell Proliferation , 2012, Diabetes.

[13]  H. Hock.  A complex Polycomb issue: the two faces of EZH2 in cancer. , 2012, Genes & development.

[14]  E. Ward,et al.  Inhibitory receptors bind Angptls and support blood stem cells and leukemia development , 2012, Nature.

[15]  Sung‐Min Ahn,et al.  Integrated Expression Profiling and Genome-Wide Analysis of ChREBP Targets Reveals the Dual Role for ChREBP in Glucose-Regulated Gene Expression , 2011, PloS one.

[16]  Yang Liu,et al.  Targeting HIF1α eliminates cancer stem cells in hematological malignancies. , 2011, Cell stem cell.

[17]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[18]  Qiang Yu,et al.  The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. , 2010, Blood.

[19]  Cheng Cheng Zhang,et al.  The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. , 2010, Cell stem cell.

[20]  O. Abdel-Wahab,et al.  Metabolism and the leukemic stem cell , 2010, The Journal of experimental medicine.

[21]  C. Thompson,et al.  The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation , 2009, Proceedings of the National Academy of Sciences.

[22]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[23]  J. Hsieh,et al.  MLL fusions: Pathways to leukemia , 2009, Cancer biology & therapy.

[24]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[25]  D. Ayer,et al.  Glucose sensing by MondoA:Mlx complexes: A role for hexokinases and direct regulation of thioredoxin-interacting protein expression , 2008, Proceedings of the National Academy of Sciences.

[26]  J. Chung,et al.  Diverse functions of VDUP1 in cell proliferation, differentiation, and diseases. , 2007, Cellular & molecular immunology.

[27]  J. Girard,et al.  ChREBP, a transcriptional regulator of glucose and lipid metabolism. , 2007, Annual review of nutrition.

[28]  D. Muoio.  TXNIP links redox circuitry to glucose control. , 2007, Cell metabolism.

[29]  S. Forman,et al.  Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. , 2007, Cancer research.

[30]  N. Sharpless,et al.  ROS as a tumour suppressor? , 2006, Nature Cell Biology.

[31]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[32]  H. Aburatani,et al.  Hepatocellular carcinoma in Txnip-deficient mice , 2006, Oncogene.

[33]  E. Giannoni,et al.  Intracellular Reactive Oxygen Species Activate Src Tyrosine Kinase during Cell Adhesion and Anchorage-Dependent Cell Growth , 2005, Molecular and Cellular Biology.

[34]  H. Masutani,et al.  Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis , 2005, Laboratory Investigation.

[35]  H. Towle,et al.  Direct Role of ChREBP·Mlx in Regulating Hepatic Glucose-responsive Genes* , 2005, Journal of Biological Chemistry.

[36]  K. Song,et al.  VDUP1 is required for the development of natural killer cells. , 2005, Immunity.

[37]  M. Magnuson,et al.  Hepatic Glucokinase Is Required for the Synergistic Action of ChREBP and SREBP-1c on Glycolytic and Lipogenic Gene Expression* , 2004, Journal of Biological Chemistry.

[38]  Y. Ishii,et al.  Loss of Thioredoxin-Binding Protein-2/Vitamin D3 Up-Regulated Protein 1 in Human T-Cell Leukemia Virus Type I-Dependent T-Cell Transformation , 2004, Cancer Research.

[39]  C. Wollheim,et al.  ChREBP Rather than USF2 Regulates Glucose Stimulation of Endogenous L-pyruvate Kinase Expression in Insulin-secreting Cells* , 2002, The Journal of Biological Chemistry.

[40]  H. Yamashita,et al.  Mechanism for Fatty Acid “Sparing” Effect on Glucose-induced Transcription , 2002, The Journal of Biological Chemistry.

[41]  M. Sakurai,et al.  A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A Ballabio,et al.  WBSCR14, a gene mapping to the Williams--Beuren syndrome deleted region, is a new member of the Mlx transcription factor network. , 2001, Human molecular genetics.

[43]  T. Tang,et al.  Human glucose‐6‐phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice , 2000, International journal of cancer.

[44]  M. Matsui,et al.  Identification of Thioredoxin-binding Protein-2/Vitamin D3 Up-regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression* , 1999, The Journal of Biological Chemistry.

[45]  S. Baer,et al.  Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. , 1997, Journal of the American Academy of Dermatology.

[46]  M. Copland,et al.  EZH2 in normal and malignant hematopoiesis , 2014, Leukemia.

[47]  R. Arceci.  PML targeting eradicates quiescent leukaemia-initiating cells , 2009 .

[48]  H. S. Jung,et al.  Optimized THP-1 differentiation is required for the detection of responses to weak stimuli , 2007, Inflammation Research.

[49]  D. Ayer,et al.  The Mlx network: evidence for a parallel Max-like transcriptional network that regulates energy metabolism. , 2006, Current topics in microbiology and immunology.